Related Experiment Video
Updated: Dec 3, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Secukinumab: Drug Survival in Clinical Practice Settings
R Ruiz-Villaverde1, L Rodríguez Fernández-Freire2, M Galán-Gutiérrez3
1Servicio de Dermatología, Hospital Universitario San Cecilio, Granada, España.
Secukinumab demonstrates high drug survival rates in plaque psoriasis patients, with 87% continuing treatment at 132 weeks. This contrasts with previous reports, highlighting secukinumab
Area of Science:
- Immunodermatology
- Pharmacology
Background:
- Secukinumab targets interleukin-17A for moderate-to-severe plaque psoriasis.
- Previous indirect comparisons suggested lower drug survival for secukinumab despite its efficacy.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
08:38Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Related Concept Videos
Cancer Survival Analysis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Products: Biologics, Biosimilars and Interchangeables
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Clinical Trials: Overview